UroToday12d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: ‘EMBARK’ing on a Novel Treatment Paradigm
PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...
UroToday12d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: EMBARK in the PSMA PET Era and Ongoing Trials
This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...
UroToday6d
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men.
Gut microbiota plays a crucial role in the development and progression of prostate cancer, with previous studies indicating that certain bacterial taxa are more abundant in castration-resistant ...
UroToday6d
Management strategies for radio-recurrent prostate cancer: a comprehensive review.
Radiation- (radio-)recurrent prostate cancer poses a significant challenge in clinical management due to its complexity and varied treatment responses. The recurrence of prostate cancer following ...
UroToday7d
Impact of Tumor Volume and Other Factors on Renal Function After Partial Nephrectomy - Beyond the Abstract
Partial nephrectomy (PN) aims to preserve renal function while achieving tumor control but understanding key predictors of renal outcomes remains essential to refine surgical approaches. In our study, ...
UroToday6d
Multiparametric MRI targeted prostate biopsy: When omit systematic biopsy?
To evaluate the detection rate for prostate cancer (PCa) performing multiparametric magnetic resonance imaging (mpMRI) fusion targeted biopsy (TPBx) combined only with ipsilateral systematic prostate ...
UroToday6d
Bladder sparing management for muscle-invasive bladder cancer after a complete clinical response: ready for prime time?-a narrative review.
A standard of care for muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). Given recent improvements in NAC and the morbidity ...
UroToday6d
MicroRNAs in seminal plasma are able to discern infertile men at increased risk of developing testicular cancer.
Male infertility is a risk factor for the development of testicular germ cell tumors. In this study, we investigated microRNA profiles in seminal plasma to identify potential noninvasive biomarkers ...
UroToday6d
Non-clear cell renal cell carcinoma narrative review: where we are in 2024.
Advances in non-clear cell renal cell carcinoma (RCC) have lagged behind clear cell RCC due to the heterogeneity and relative rarity of the disease. However, more advanced molecular and genetic ...
UroToday6d
Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?
Optimal treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC) are evolving with novel multimodal approaches. For well-selected patients, early local radiotherapy can play a ...
UroToday5d
Value-Based Care and Reducing Prescription Drug Costs
Ruchika Talwar hosts Daniel Sentana Lledo to discuss the concept of time toxicity in prostate cancer treatment. Time toxicity measures the amount of time patients spend in the healthcare system and ...
UroToday5d
Managing BCG-Unresponsive NMIBC: Treatment Strategies, Progression, and Emerging Therapies
Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner presents findings from a phase ...